Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Type 2 Diabetes Mellitus (TRANSCEND-T2D-1)
NCT06354660Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of retatrutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Apr 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06354660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354660.